当前位置： SCI文献检索 > Clinical Breast Cancer期刊下所有文献 > Isolated sternal involvement in breast cancer: is it truly stage IV disease?

Isolated sternal involvement in breast cancer: is it truly stage IV disease?

Abstract：

PURPOSE:There is no consensus regarding treatment for patients with breast cancer and isolated sternal involvement. Though classified as AJCC stage IV, this group of patients may have prolonged distant disease free survival. PATIENTS AND METHODS:Retrospective case series of 8 patients with isolated sternal recurrence. Information regarding age, menopausal status, hormonal receptor status, HER2 status, initial treatment, time to sternal recurrence, treatment of sternal involvement, and outcome was obtained. RESULTS:Median follow-up, 6 years. Seven of 8 diagnosed with metachronous sternal recurrence at a median of 3 years from initial breast cancer diagnosis, 1 with sternal involvement at initial diagnosis. Seven of 8 are alive, with one death from metastatic breast cancer 10 years after sternal recurrence. Six of 8 are without evidence of distant spread, 2 in continuous complete remission (CR) at 7 and 14 years from sternal recurrence. CONCLUSION:While a small cohort, the excellent survival of the group identifies this as a distinct subset of metastatic disease, requiring special treatment considerations. Isolated sternal involvement could represent direct local-regional extension rather than systemic spread.

journal_name

Clin Breast Cancer

journal_title

Clinical breast cancer

authors

Chockalingam P,Astrow AB,Klein P,Huang Y,Reichman BS,Citron ML

doi

10.1016/j.clbc.2011.03.017

subject

Has Abstract

pub_date

2011-06-01 00:00:00

pages

191-4

issue

3

eissn

1526-8209

issn

1938-0666

pii

S1526-8209(11)00018-8

journal_volume

11

pub_type

杂志文章

相关文献

Clinical Breast Cancer文献大全
  • Comparison of toxicity experienced by older versus younger patients enrolled in breast cancer clinical trials.

    abstract：BACKGROUND:Elderly patients form a large proportion of patients with breast cancer but are underrepresented in clinical trials. We examined whether elderly patients experience more toxicity than younger patients within breast cancer clinical trials. MATERIALS AND METHODS:All breast cancer trials open from 1999 to 2012...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2014.09.002

    authors： Mariano C,Francl M,Pope J,Wong L,Lim HJ,Lohrisch C

    更新日期：2015-02-01 00:00:00

  • A Reappraisal of the Comparative Effectiveness of Lumpectomy Versus Mastectomy on Breast Cancer Survival: A Propensity Score-Matched Update From the National Cancer Data Base (NCDB).

    abstract：BACKGROUND:Recent observational studies are concerning because they document rising mastectomy rates coinciding with more than a dozen reports that lumpectomy has better overall survival (OS) than mastectomy. Our aim was to determine if there were differences in OS of matched breast cancer patients undergoing lumpectom...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2019.02.006

    authors： Landercasper J,Ramirez LD,Borgert AJ,Ahmad HF,Parsons BM,Dietrich LL,Linebarger JH

    更新日期：2019-06-01 00:00:00

  • Added Value of Breast MRI for Preoperative Diagnosis of Ductal Carcinoma In Situ: Diagnostic Performance on 362 Patients.

    abstract：INTRODUCTION:The purpose of this study was to evaluate the added value of breast magnetic resonance imaging (MRI) in preoperative diagnosis of ductal carcinoma in situ (DCIS). We reviewed our institution database of 3499 consecutive patients treated for breast cancer. PATIENTS AND METHODS:A total of 362 patients with ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2016.12.007

    authors： Petrillo A,Fusco R,Petrillo M,Triunfo F,Filice S,Vallone P,Setola SV,Rubulotta M,Di Bonito M,Rinaldo M,D'Aiuto M,Brunetti A

    更新日期：2017-06-01 00:00:00

  • Will we need lymph node dissection at all in the future?

    abstract：:Traditionally in the treatment of primary breast cancer, axillary lymph node dissection (ALND) plays an important role. However, a substantial and increasing percentage of patients appear to have no nodal involvement and have been subjected to ALND unnecessarily. The first reason to perform an ALND is axillary nodal s...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/cbc.2002.n.034

    authors： Bourez RL,Rutgers EJ,Van De Velde CJ

    更新日期：2002-12-01 00:00:00

  • BMI and Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer: A Study and Meta-Analysis.

    abstract：INTRODUCTION:There is only limited data from clinical practice on the relevance of body mass index (BMI) on pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC). PATIENTS AND METHODS:The impact of BMI on pCR and survival outcome was examined in 324 patients wi...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,meta分析

    doi：10.1016/j.clbc.2016.02.018

    authors： Erbes T,Stickeler E,Rücker G,Buroh S,Asberger J,Dany N,Thornton S,Iborra S,Hirschfeld M,Gitsch G,Mayer S

    更新日期：2016-08-01 00:00:00

  • Bioelectrical impedance for detecting and monitoring patients for the development of upper limb lymphedema in the clinic.

    abstract：BACKGROUND:Single-frequency bioelectrical impedance (BI) has been used to measure extracellular fluid in the upper limbs. The purpose of the study was to evaluate BI's ability to detect and monitor upper limb changes in based upon the extent of various treatments and to assess its practicality. METHODS:Patients with n...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2012.01.004

    authors： Vicini F,Shah C,Lyden M,Whitworth P

    更新日期：2012-04-01 00:00:00

  • A Retrospective Analysis of the Relationship Between the Result of BRCA1/2 Genetic Testing and Surgical Method Selection in Japan.

    abstract：BACKGROUND:We studied the extent of BRCA1/2 genetic testing to help select the surgical approach for patients with breast cancer in Japan remains unclear. PATIENTS AND METHODS:The study subjects were female patients with primary unilateral invasive breast cancer considered as candidates for breast-conserving surgery w...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2020.08.004

    authors： Inuzuka M,Watanabe C,Yokoyama S,Kuwayama T,Akashi-Tanaka S,Arai M,Nakamura S,Registration Committee of the Japanese HBOC consortium.

    更新日期：2020-08-20 00:00:00

  • Detection of breast cancer in an FDG-PET cancer screening program: results of a nationwide Japanese survey.

    abstract：BACKGROUND:The [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) cancer screening program is defined as cancer screening for asymptomatic subjects using FDG-PET/computed tomography with or without combination of other screening tests. The aim of this study was to analyze the detection rate and effectivene...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2014.09.008

    authors： Minamimoto R,Senda M,Jinnouchi S,Terauchi T,Yoshida T,Inoue T

    更新日期：2015-04-01 00:00:00

  • Taxanes and capecitabine in combination: rationale and clinical results.

    abstract：:The clinical utility of capecitabine as a single agent in metastatic breast cancer has been demonstrated with significant responses seen in women already treated with anthracyclines and taxanes. A phase II study in older women with metastatic breast cancer demonstrated capecitabine to be an effective front-line therap...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/cbc.2002.n.004

    authors： Maher JF,Villalona-Calero MA

    更新日期：2002-01-01 00:00:00

  • Rationale and design of a phase III trial of adjuvant sequential epirubicin/ cyclophosphamide and taxane versus concurrent epirubicin/taxane in operable node-positive breast cancer.

    abstract：:The sequential use of a doxorubicin combination followed by paclitaxel has been reported to improve disease-free and overall survival in patients with node-positive breast cancer beyond that obtained with doxorubicin/cyclophosphamide combinations. Epirubicin is associated with less cardiotoxicity than doxorubicin and ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/cbc.2000.s.010

    authors： Perez EA

    更新日期：2000-09-01 00:00:00

  • Single Nucleotide Polymorphisms in the Acylphosphatase 2 Gene and The SNP-SNP Interactions on the Risk of Breast Cancer in Chinese Han Women.

    abstract：INTRODUCTION:The purpose of this study was to investigate the impact of single nucleotide polymorphisms (SNPs) in the acylphosphatase 2 gene and the SNP-SNP interactions on breast cancer (BC) risk in Chinese Han women. PATIENTS AND METHODS:A logistic regression model was used to examine the association between SNPs an...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2017.09.003

    authors： Wu J,Wang S,Liu F,Li S

    更新日期：2018-06-01 00:00:00

  • The Role of Contrast-Enhanced Ultrasound in the Diagnosis and Pathologic Response Prediction in Breast Cancer: A Meta-analysis and Systematic Review.

    abstract：PURPOSE:To determine the overall performance of contrast-enhanced ultrasound (CEUS) in differentiating between benign and malignant breast lesions and in predicting the pathologic response to neoadjuvant chemotherapy (NAC) in patients with breast cancer (BC). MATERIALS AND METHODS:Articles published up to April 2019 w...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2020.03.002

    authors： Zhou SC,Le J,Zhou J,Huang YX,Qian L,Chang C

    更新日期：2020-08-01 00:00:00

  • ER-α36 Interactions With Cytosolic Molecular Network in Acquired Tamoxifen Resistance.

    abstract：:According to the World Health Organization (WHO) published data in 2015; breast cancer is the most prevalent and the second leading cause of cancer death among females. As approximately 70% of breast cancer tumor cells are estrogen receptor (ER) positive, primary therapeutic agents such as Anti-estrogens were produced...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clbc.2017.03.013

    authors： Teymourzadeh A,Mansouri S,Farahmand L,Hosseinzade A,Majidzadeh-A K

    更新日期：2017-10-01 00:00:00

  • The Influence of Histologic Grade on Outcomes of Elderly Women With Early Stage Breast Cancer Treated With Breast Conserving Surgery With or Without Radiotherapy.

    abstract：BACKGROUND:Two large randomized trials, CALGB 9343 and PRIME II, support omission of radiotherapy after breast conserving surgery (BCS) in elderly women with favorable-risk early stage breast cancer intending to take endocrine therapy. However, patients with grade 3 histology were underrepresented on these trials. We h...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2020.05.007

    authors： Escott CE,Zaenger D,Switchencko JM,Lin JY,Abugideiri M,Arciero CA,Pfister NT,Xu KM,Meisel JL,Subhedar P,Torres M,Curran WJ,Patel PR

    更新日期：2020-12-01 00:00:00

  • Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.

    abstract：BACKGROUND:Postmenopausal women with hormone receptor-positive (HR(+)) breast cancer in whom disease progresses or there is recurrence while taking a nonsteroidal aromatase inhibitor (NSAI) are usually treated with exemestane (EXE), but no single standard of care exists in this setting. The BOLERO-2 trial demonstrated ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1016/j.clbc.2013.08.011

    authors： Pritchard KI,Burris HA 3rd,Ito Y,Rugo HS,Dakhil S,Hortobagyi GN,Campone M,Csöszi T,Baselga J,Puttawibul P,Piccart M,Heng D,Noguchi S,Srimuninnimit V,Bourgeois H,Gonzalez Martin A,Osborne K,Panneerselvam A,Taran T,Sa

    更新日期：2013-12-01 00:00:00

  • The Accuracy of Breast MR Imaging for Measuring the Size of a Breast Cancer: Analysis of the Histopathologic Factors.

    abstract：BACKGROUND:The objective of the study was to compare the accuracy of different magnetic resonance (MR) sequences for measuring tumor size and to evaluate whether the imaging and histopathologic features affect the accuracy of the tumor size estimation on the MR sequence. PATIENTS AND METHODS:Eight hundred women were i...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2016.07.007

    authors： Choi WJ,Cha JH,Kim HH,Shin HJ,Chae EY

    更新日期：2016-12-01 00:00:00

  • Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results.

    abstract：:Trastuzumab/chemotherapy combinations have already shown superior results in metastatic breast cancer patients. The purpose of this study is to determine the clinical efficacy of neoadjuvant trastuzumab and docetaxel in women with locally advanced breast cancer, with or without metastatic disease. Treatment-naive wome...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.3816/cbc.2003.n.040

    authors： Van Pelt AE,Mohsin S,Elledge RM,Hilsenbeck SG,Gutierrez MC,Lucci A Jr,Kalidas M,Granchi T,Scott BG,Allred DC,Chang JC

    更新日期：2003-12-01 00:00:00

  • Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.

    abstract：BACKGROUND:The ExteNET trial demonstrated improved invasive disease-free survival (iDFS) with neratinib, an irreversible pan-HER tyrosine kinase inhibitor, versus placebo in patients with human epidermal growth factor receptor 2-positive (HER2+)/hormone receptor-positive (HR+) early-stage breast cancer (eBC). PATIENTS...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2020.09.014

    authors： Chan A,Moy B,Mansi J,Ejlertsen B,Holmes FA,Chia S,Iwata H,Gnant M,Loibl S,Barrios CH,Somali I,Smichkoska S,Martinez N,Alonso MG,Link JS,Mayer IA,Cold S,Murillo SM,Senecal F,Inoue K,Ruiz-Borrego M,Hui R,Dendulu

    更新日期：2020-10-06 00:00:00

  • Targeting the ubiquitin-proteasome pathway in breast cancer.

    abstract：:The 26S proteasome is an adenosine triphosphate-dependent multicatalytic protease that is responsible for most nonlysosomal intracellular protein degradation. To be selected for proteasomal degradation, proteins must be previously tagged with a polyubiquitin chain, which is then recognized by the proteasome; the ubiqu...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/cbc.2004.n.020

    authors： Cardoso F,Ross JS,Picart MJ,Sotiriou C,Durbecq V

    更新日期：2004-06-01 00:00:00

  • Implant-sparing Mastectomy: An Alternative for Women Undergoing Mastectomy With Retropectoral Implants.

    abstract：INTRODUCTION:Implant-sparing mastectomy (ISM) is a skin-sparing mastectomy that preserves a retropectoral implant and potentially eliminates the need for tissue expansion or complex reconstruction. This study aimed to determine oncologic and surgical outcomes and reconstructive patterns in patients undergoing ISM. PAT...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2019.08.007

    authors： Burke EE,Laronga C,Sun W,DeBiase S,Naqvi SMH,Fridley B,Czerniecki BJ,Hoover SJ,Khakpour N,Kiluk JV,Lee MC

    更新日期：2020-02-01 00:00:00

  • The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ.

    abstract：BACKGROUND:Although magnetic resonance imaging (MRI) is a useful imaging modality for invasive cancer, its role in preoperative surgical planning for ductal carcinoma in situ (DCIS) has not been established. We sought to determine whether preoperative MRI affects surgical treatment and outcomes in women with pure DCIS....

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.3816/CBC.2011.n.006

    authors： Itakura K,Lessing J,Sakata T,Heinzerling A,Vriens E,Wisner D,Alvarado M,Esserman L,Ewing C,Hylton N,Hwang ES

    更新日期：2011-03-01 00:00:00

  • Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.

    abstract：:Breast cancer is the most common type of cancer among women and the second leading cause of cancer death in the United States. Metastatic breast cancer is considered incurable, and treatment is aimed at palliating symptoms, achieving remission, and prolonging survival. Treatment options for metastatic disease vary bas...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clbc.2011.07.001

    authors： Sachdev JC,Jahanzeb M

    更新日期：2012-02-01 00:00:00

  • Breast Reconstruction After Mastectomy: A Survey of Surgeons' and Patients' Perceptions.

    abstract：BACKGROUND:Breast reconstruction after mastectomy is important in breast cancer care. MATERIALS AND METHODS:A cross-sectional study was designed to assess surgeons' and patients' perceptions toward breast reconstruction. Questionnaires were distributed to general and breast surgeons in East Coast Malaysian hospitals a...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2018.04.012

    authors： Ishak A,Yahya MM,Halim AS

    更新日期：2018-10-01 00:00:00

  • Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.

    abstract：BACKGROUND:Triple-negative breast cancer (TNBC) is an aggressive disease without established targeted treatment options for patients with metastatic disease. This study was undertaken to evaluate potentially actionable biomarkers in a large cohort of TNBC and compare them with non-TNBCs. MATERIALS AND METHODS:We evalu...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2015.04.008

    authors： Millis SZ,Gatalica Z,Winkler J,Vranic S,Kimbrough J,Reddy S,O'Shaughnessy JA

    更新日期：2015-12-01 00:00:00

  • Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunochemistry Analysis.

    abstract：PURPOSE:Oncotype DX (ODX) predicts breast cancer recurrence risk, guiding the choice of adjuvant treatment. In many countries, access to the test is not always available. We used correlation between phenotypical tumor characteristics, quantitative classical immunohistochemistry (IHC), and recurrence score (RS) assessed...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2020.04.012

    authors： Marazzi F,Barone R,Masiello V,Magri V,Mulè A,Santoro A,Cacciatori F,Boldrini L,Franceschini G,Moschella F,Naso G,Tomao S,Gambacorta MA,Mantini G,Masetti R,Smaniotto D,Valentini V

    更新日期：2020-10-01 00:00:00

  • New horizons in treating metastatic disease.

    abstract：:The management of metastatic breast cancer is changing as a consequence of extraordinary discoveries in cancer research and the development of more advanced diagnostic technologies. Although traditional chemotherapeutics such as anthracyclines and taxanes still represent the mainstay of treatment for this disease, new...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CBC.2001.n.002

    authors： Cristofanilli M,Hortobagyi GN

    更新日期：2001-01-01 00:00:00

  • Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials.

    abstract：:Intravenous bisphosphonates are the preferred treatment to prevent skeletal complications for patients with breast cancer and bone metastases. Pamidronate, a single-nitrogen bisphosphonate, was the early standard of care for such patients based on 2 large, placebo-controlled trials involving 754 patients. Zoledronic a...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CBC.2005.n.014

    authors： Gordon DH

    更新日期：2005-06-01 00:00:00

  • Equivalent Survival With Mastectomy or Breast-conserving Surgery Plus Radiation in Young Women Aged < 40 Years With Early-Stage Breast Cancer: A National Registry-based Stage-by-Stage Comparison.

    abstract：BACKGROUND:Studies have shown that young patients with early-stage breast cancer (BC) are increasingly undergoing mastectomy instead of breast-conserving therapy (BCT) consisting of lumpectomy and radiation. We examined the difference in outcomes in young women (aged < 40 years) who had undergone BCT versus mastectomy....

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2015.03.012

    authors： Ye JC,Yan W,Christos PJ,Nori D,Ravi A

    更新日期：2015-10-01 00:00:00

  • Evaluation of Multifocality and Multicentricity With Breast Magnetic Resonance Imaging in Each Breast Cancer Subtype.

    abstract：INTRODUCTION:The purpose of this study was to evaluate whether diagnostic performance of breast magnetic resonance imaging (MRI) for detection of multifocality and multicentricity (MFMC) of breast cancer (BC) can be influenced by different histotypes or immunophenotypes in newly diagnosed patients with breast cancer. ...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章

    doi：10.1016/j.clbc.2017.10.012

    authors： Prochowski Iamurri A,Ponziani M,Macchini M,Fogante M,Pistelli M,De Lisa M,Berardi R,Giuseppetti GM

    更新日期：2018-04-01 00:00:00

  • Role of Magnetic Resonance Imaging in Detection of Pathologic Complete Remission in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Meta-analysis.

    abstract：:Pathologic complete remission after neoadjuvant chemotherapy has a role in guiding the management of breast cancer. The present meta-analysis examined the accuracy of contrast-enhanced magnetic resonance imaging (CE-MRI) and diffusion-weighted magnetic resonance imaging (DW-MRI) in detecting the response to neoadjuvan...

    journal_title：Clinical breast cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.clbc.2016.12.010

    authors： Gu YL,Pan SM,Ren J,Yang ZX,Jiang GQ

    更新日期：2017-07-01 00:00:00